FOXO Technologies Announces Receipt Of Notice Of Non-Compliance With NYSE Continued Listing Requirements; Reaffirms Commitment To Regaining Compliance
- SEC Filing
- SEC Filing
8-K - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
8-K/A - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
10-Q - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
FOXO Technologies Inc. (NYSE:FOXO) (the "Company" or "FOXO"), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor ("Investor") to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company's growth strategy.
MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC:RNVA) ("Rennova"). The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024. The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, I
MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. ("Myrtle"), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment. FOXO completed the acquisition of Myrtle re
MINNEAPOLIS, MN, July 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) (the "Company" or "FOXO"), reports that it has received an official notice of noncompliance (the "NYSE American Notice") from NYSE Regulation ("NYSE") stating that the Company is not in compliance with Section 1003(a)(ii) of the Company Guide since it reported stockholders' deficit of ($14.9) million as of March 31, 2024, and losses from continuing operations and/or net losses in its three most recent fiscal years ended December 31, 2023 (the "Delinquency"). Mark White, Interim CEO of FOXO, said, "The delinquency was due to the previously disclosed short-term capital allocation strategies. While w
3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
4 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
SC 13D - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
SC 13D/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
SC 13D/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC:RNVA) ("Rennova"). The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024. The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, I
MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. ("Myrtle"), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment. FOXO completed the acquisition of Myrtle re
FOXO Technologies Inc. (NYSEAM:FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023. "I am very proud of our accomplishments during the second quarter," said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. "In addition to streamlining our capital structure, we continued to advance our growth initiatives through product expansion and scientific discovery. Through our partnerships with leading academic research and healthcare institutions, we are exploring new insights in longevity science and health, while at the same time developing new and exciting AI driven consumer
FOXO Technologies Inc. (NYSE:FOXO) (the "Company"), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III brings over 20 years of experience in the financial services Sector. He currently serves as President of Colt Capital LLC, a Florida-based company, whose principal activities focus on advising emerging market companies on private and public financing strategies. Prior to founding Colt Capital LLC, Mr. deWolf was a Senior Vice President at Oppenheimer and Company, where he oversaw a variety of financing activities. Mr. deWolf also served as Vice President at Prudential Securities and as a bond broker for Tucker Anthony. Mr. deWolf is
FOXO Technologies Inc. (NYSEAM:FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced the resignation of Taylor Fay as Chief Operating Officer of the Company, effective April 28, 2023. "I am extremely proud of our achievements throughout Taylor's tenure at FOXO," said Tyler Danielson, interim CEO, and Chief Technology Officer at FOXO. "His leadership and work ethic inspired those around him, and we are a more talented and dedicated team because of his contributions. The Board and executive leadership thank Taylor for his leadership and wish him well in his future endeavors." "Throughout my tenure at FOXO, I have worked alongside an exceptional team